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OBJECTIVES To test the hypothesis that antioxidant therapy would improve endothelial function in
smokers.
BACKGROUND Several studies have documented a beneficial effect of short-term oral or parenteral vitamin C
on endothelial physiology in subjects with early arterial dysfunction. Possible long-term
effects of vitamin C on endothelial function, however, are not known.
METHODS We studied the effects of short- and long-term oral vitamin C therapy on endothelial function
in 20 healthy young adult smokers (age 36 6 6 years, 8 male subjects, 21 6 10 pack-years).
Each subject was studied at baseline, 2 h after a single dose of 2 g vitamin C and 8 weeks after
taking 1 g vitamin C daily, and after placebo, in a randomized double-blind crossover study.
Blood samples were analyzed for plasma ascorbate levels and endothelial function was
measured as flow-mediated dilation of the brachial artery, using high resolution ultrasound.
Nitroglycerin-mediated dilation (endothelium-independent) was also measured at each visit.
RESULTS At baseline, plasma ascorbate level was low in the smokers (42 6 21 mmol/liter; normal range,
50 to 150 mmol/liter), increased with vitamin C therapy after 2 h to 120 6 54 mmol/liter (p ,
0.001) and remained elevated after eight weeks of supplementation at 92 6 32 mmol/liter
(p , 0.001, compared with placebo). Flow-mediated dilation, however, increased at 2 h (from
2.8 6 2.0% to 6.3 6 2.8%, p , 0.001), but there was no sustained beneficial effect after eight
weeks (3.9 6 3.2%, p 5 0.26). Nitroglycerin-mediated dilation was unchanged throughout.
CONCLUSION Oral vitamin C therapy improves endothelial dysfunction in the short term in healthy young
smokers, but it has no beneficial long-term effect, despite sustained elevation of plasma
ascorbate levels. (J Am Coll Cardiol 2000;35:1616–21) © 2000 by the American College of
Cardiology
Smoking is a major cardiovascular risk factor and is associ-
ated with dose-dependent arterial endothelial dysfunction
(1), a key early event in atherogenesis (2). The cause of
endothelial dysfunction in smokers is not known, but it has
been attributed to increased oxidative stress that may reduce
the bioavailability of endothelium-derived nitric oxide, lead-
ing to impairment in vasodilator function (3). Previous
observations have suggested that smoke-related endothelial
dysfunction is potentially reversible after withdrawal from
active or passive smoking (1,4). As such reversibility is
incomplete, however, and rates of smoking cessation remain
low (5), there is a pressing need to identify other strategies
that might improve arterial health in smokers.
As smokers have low levels of antioxidant vitamin C,
presumably due to increased consumption by prooxidants in
cigarette smoke (6), antioxidant therapy is one such possi-
bility. Indeed, recent human studies have shown that
short-term parenteral administration of antioxidant vitamin
C acutely reduces oxidative damage (7) and may improve
endothelial function in smokers (8,9). The short-term
beneficial effects of vitamin C on vascular reactivity have
also been demonstrated in other conditions associated with
endothelial dysfunction and increased oxidative stress, such
as hypercholesterolemia (10), coronary artery disease (11),
diabetes (12) and hypertension (13).
Much less well studied, but of greater practical relevance,
are the vascular effects of longer-term supplementation with
orally administered vitamin C. To our knowledge, this has
not been investigated previously in smokers. We therefore
aimed to examine whether a single oral dose of vitamin C
improves endothelial function in asymptomatic smokers in
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the short term, and whether there are any longer-term
beneficial effects after eight weeks of daily therapy with this
antioxidant.
METHODS
Subjects. We studied 20 consecutive healthy volunteers
who fulfilled the prespecified entry criteria: age 18 to 50
years, regular smoking history of 6 to 40 pack-years, no
hypertension, no diabetes mellitus, no familial hypercholes-
terolemia, no clinically evident atherosclerosis, no family
history of premature cardiovascular disease and not taking
oral contraceptives, antioxidant vitamins or cardioactive
drugs. All subjects had endothelial dysfunction at baseline,
defined as flow-mediated dilation (FMD) less than the
population mean for vessel size (14). On average, the
baseline FMD levels were 2.0 SDs below the population
mean (range, 0.2 to 3 SDs). All subjects continued their
normal smoking habit for the duration of the study. This
investigation was approved by the local committee on
ethical practice and all subjects gave their informed consent.
Study design. Subjects were randomized to received vita-
min C or matching placebo in a double-blind crossover
study. To assess the short-term effect of vitamin C, each
subject was studied at baseline and 2 h after a single oral
dose of 2 g of vitamin C and after placebo. This dose was
chosen to try to replicate the beneficial effects observed by
Levine et al. (11) in their study of short-term oral vitamin C
therapy in older subjects with established coronary artery
disease. To assess the long-term effect of vitamin C, each
subject was studied eight weeks after taking 1 g of vitamin
C and after placebo. Each of these studies took place 1 to
2 h after the last dose of vitamin C. The daily dose of 1 g/d
was chosen on the basis of the detailed pharmacologic
studies of Levine et al. (15), demonstrating that complete
plasma saturation of plasma ascorbate occurs at a dose of 1 g
daily and increasing the dose above 1 g/d only activates
urinary excretion mechanisms. Theoretically, at doses of
.1 g daily, a risk of kidney stones, uricosuria, vitamin B12
deficiency, iron overload and mutagenicity exists (16). Thus,
every subject was examined on six occasions (baseline, 2 h
and eight weeks after vitamin C, at rebaseline after four
weeks’ washout and 2 h and eight weeks after placebo). In
each case, subjects were fasting (other than for their study
medications). One scan in one subject (2 h after vitamin C
treatment) was excluded because of poor image quality.
Vitamin C and the image-matched placebo preparations
used in this study were provided by Blackmores Health
Products (Sydney, Australia).
Ultrasound studies. All studies were performed using a
128XP/10 mainframe (Acuson; Mountain View, Califor-
nia) with a 7.0-MHz linear array transducer, as previously
described (1,2). Brachial artery diameter was measured from
B-mode ultrasound images. Scans were obtained at rest,
during reactive hyperemia, again at rest and after sublingual
nitroglycerin. The artery was scanned in longitudinal sec-
tion 2 to 15 cm above the elbow. A resting scan was
recorded, and arterial flow velocity was measured using a
Doppler signal. Increased flow was induced by inflation of a
pneumatic tourniquet placed around the forearm (distal to
the scanned part of the artery) to a pressure of 250 mm Hg
for 4.5 min, followed by release. A second scan was taken
continuously for 30 s before and 90 s after cuff deflation,
including a flow velocity recording for the first 15 s after the
cuff was released. Thereafter, 10 to 15 min was allowed for
vessel recovery, after which a further resting scan was taken.
Sublingual nitroglycerin (glyceryl trinitrate spray, 400 mg)
was then administered, and 3 to 4 min later the last scan was
acquired.
Vessel diameter was measured by two independent ob-
servers who were “blinded” to the subject’s clinical details
and stage of the experiment, as previously described (1,2).
Measurements were taken from the anterior to the posterior
“m” line at end-diastole, incident with the R-wave on a
continuously recorded ECG. For the reactive hyperemia
scan, diameter measurements were taken 45 to 60 s after cuff
deflation. The vessel diameter in scans after reactive hyper-
emia and nitroglycerin administration was expressed as the
percentage relative to the average diameter of the artery in
the two resting (control) scans (100%). This method has
been shown previously to be accurate and reproducible for
measurement of small changes in arterial diameter (17),
with low interobserver error for measurement of FMD and
nitrate-induced arterial dilation (2,17).
Ascorbate and serum lipoproteins. Blood samples for
determination of serum lipoproteins and ascorbate levels
were taken immediately before each ultrasound examina-
tion. The samples were taken 2 h after the initial 2-g dose
of vitamin C and placebo, and 1 to 2 h after taking the last
1-g dose after eight weeks of therapy. The plasma levels of
ascorbate were determined by high performance liquid
chromatography. Fasting serum total cholesterol and tri-
glyceride concentrations were measured using standard
enzymatic methods (Boehringer Mannheim GmbH) with a
fully automated analyzer (Hitachi Ltd; Tokyo, Japan).
High-density lipoprotein cholesterol (HDL cholesterol)
was measured after precipitation with dextran sulfate-
magnesium. Low-density lipoprotein concentration (LDL
cholesterol) was calculated using the Friedewald equation.
Statistical methods. Repeated-measures analysis of vari-
ance (ANOVA) for 2 3 2 crossover design was used to test
Abbreviations and Acronyms
ANOVA 5 analysis of variance
FMD 5 flow-mediated dilation
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
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whether the changes in study variables from baseline to 2 h
and baseline to eight weeks were significantly different
between vitamin C and placebo (procedure Mixed in Sta-
tistical Analysis System; SAS Institute Inc.; Cary, North
Carolina). We used the Wallenstein-Fisher statistical model
(18) that included fixed main effects for treatment, se-
quence, period and time, as well as sequence-by-time,
period-by-time and treatment-by-time interaction effects.
Treatment effects were calculated after taking into account
any carryover effects. There were two repeated measure-
ments for each outcome variable; the change from baseline
to 2 h and the change from baseline to eight weeks. If the
ANOVA revealed statistically significant treatment-by-time
interaction, the Fisher least significant difference multiple
comparison procedure was used to test the equality of the
pairwise treatment group means. These tests were carried
out as linear contrasts using the same statistical model. For
correlation analysis, Pearson’s correlation coefficients were
calculated. Descriptive data are presented as mean 6 SD
(unless stated otherwise), and significance was inferred at
two tailed p , 0.05.
With 20 subjects enrolled in a crossover trial, this study
had .90% power to detect a vitamin C-related improve-
ment of 2.5% in FMD, compared with placebo, at the p ,
0.05 level.
RESULTS
The characteristics of study subjects (8 male, 12 female)
were as follows: history of smoking, 21 6 10 pack-years;
body mass index, 24.3 6 3.5 kg/m2; total cholesterol, 5.0 6
1.0 mmol/liter; LDL cholesterol, 3.0 6 0.9 mmol/liter;
HDL cholesterol, 1.42 6 0.41 mmol/liter; triglycerides,
1.16 6 0.66 mmol/liter; and blood pressure, 122 6 13/70 6
9 mm Hg.
Baseline plasma ascorbate level was 42.2 6 20.7 mmol/
liter; range was 5.0 to 83.0 mmol/liter (normal range, 50 to
150 mmol/liter) (19). Oral ingestion of 2 g of vitamin C
resulted in an increase in plasma ascorbate concentration
after 2 h to 120 6 54 mmol/liter, and after eight weeks of
supplementation with vitamin C 1 g daily, a sustained
elevation in plasma ascorbate levels was seen, to 92 6 32
mmol/liter (p , 0.001).
The mean values for FMD in each examination are
shown in Figure 1. In a repeated-measures ANOVA model,
the overall treatment effect was significant (p , 0.002), but
there was a significant treatment-by-time interaction (p ,
0.01) indicating that the effect was different at 2 h and eight
weeks. After the single 2-g dose of vitamin C, FMD
improved from 2.8 6 2.0% to 6.3 6 2.8% (p , 0.001).
After eight weeks of supplementation with vitamin C,
FMD measured 3.9 6 3.1% and was not significantly
different from placebo (p 5 0.26).
Treatment with vitamin C had no significant short- or
long-term effects on nitrate-mediated dilation, baseline
vessel diameter or reactive hyperemia (the stimulus for
brachial artery dilation) (Table 1).
Serum lipoprotein levels were measured at baseline and at
eight weeks. Treatment with vitamin C had no significant
effects on serum total cholesterol, HDL cholesterol or
triglycerides concentrations (data not shown).
Ascorbate level at baseline was not correlated with FMD
(r 5 0.0, p 5 0.99); however, there was a weak correlation
(r 5 0.43, p 5 0.07) between FMD values and plasma
ascorbate concentration after the single oral dose of vitamin
C. Placebo treatment did not alter any measured parameters
at 2 h or at eight weeks.
DISCUSSION
Smoking remains the major modifiable risk factor for
vascular disease. Although many smokers wish to quit their
habit, only a minority succeed once smoking behavior is
established (5). To our knowledge, no studies have previ-
ously examined the potential reversibility of smoke-related
vascular disease with any long-term strategy, however, other
than smoking cessation. In this randomized, placebo-
controlled, crossover trial, we have found that although a
single dose of vitamin C improves vascular reactivity in the
short term in adult smokers with baseline endothelial
dysfunction, there is no significant longer-term beneficial
arterial effect.
Figure 1. Values for FMD (mean 6 SEM) at each visit, which
improved significantly 2 h after treatment with vitamin C, but no
sustained treatment effect was seen at eight weeks.
Table 1. Effect of Oral Vitamin C Therapy on Measured
Vascular Parameters
Baseline 2 h 8 wk
FMD (%) 2.8 6 2.0 6.3 6 2.8* 3.9 6 3.1
NMD (%) 15.9 6 4.4 17.1 6 4.9 16.2 6 4.4
Vessel size (mm) 3.8 6 0.47 3.8 6 0.47 3.8 6 0.48
Hyperemia (%) 567 6 351 446 6 236 693 6 483
*p , 0.001 compared with placebo.
FMD 5 flow-mediated dilation; NMD 5 nitrate-mediated dilation.
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Smoking and endothelial dysfunction. Previous studies
have shown that cigarette smoking (1,20) and exposure to
passive smoking (21) are associated with arterial endothelial
dysfunction, a key early event in atherosclerosis. The exact
cause of vascular dysfunction in smokers is not known, but
it has been attributed to increased oxidative stress that may
lead to inactivation of endothelium-derived nitric oxide by
oxygen-derived free radicals (3). Nitric oxide is released by
normally functioning endothelium and its release (or that of
metabolite[s] closely related to nitric oxide) is responsible
for endothelium-dependent arterial relaxation, which can be
induced (for example) by increasing flow and shear stress
(22). Preserved nitric oxide bioavailability may be a partic-
ularly important protective mechanism in the vessel wall, as
nitric oxide has antiplatelet, antiadhesive and antiprolifera-
tive effects in addition to its role as a vasodilator (22).
Cigarette smoke contains large amounts of free radicals
and pro-oxidants, which in biological systems can undergo
redox cycling to produce reactive oxidant species (23). In
addition, superoxide anion radical derived from cigarette
smoke may react with endothelium-derived nitric oxide
directly or via formation of peroxynitrite, a highly reactive
intermediate with cytotoxic activity (24). Oxygen-derived
free radicals within the vasculature may also initiate the
oxidation of lipoproteins, which in turn may interfere
directly with vascular function, including vessel relaxation
(25). Furthermore, free radicals in cigarette smoke may
increase the depletion of natural antioxidants, such as
vitamin C, and thereby increase their own pro-oxidant
potential. Indeed, plasma levels of ascorbate are lower in
smokers compared with healthy control subjects (6).
Short-term effects of vitamin C. For these reasons, we
and others have hypothesized that vitamin C therapy might
improve smoke-related arterial endothelial dysfunction.
Several recent studies using high dose parenteral adminis-
tration of vitamin C have shown that its infusion acutely
improves endothelial function in smokers (8,9), as well as in
other conditions that may be associated with increased
oxidative stress, such as coronary artery disease (13), hyper-
cholesterolemia (10), diabetes (12), chronic heart failure
(26) and hypertension (27). Heitzer et al. (8) measured
forearm microvascular responses to acetylcholine in long-
term smokers and observed a marked improvement in
acetylcholine-induced vasodilation with concomitant in-
traarterial high dose infusion of vitamin C. Similarly,
Motoyama et al. (9) observed a significant short-term
improvement in brachial artery endothelial function after
acute parenteral infusion of vitamin C in smokers. Con-
comitantly, a significant decrease was seen in the plasma
levels of thiobarbituric acid–reactive substances, suggesting
an acute reduction in oxidative stress (9).
To our knowledge, short-term effects of long-term oral
vitamin C therapy in smokers have not been previously
studied; however, Levine et al. (11) observed a significant
improvement in endothelial function in patients with cor-
onary heart disease (9 of 26 of whom were smokers), acutely
after a single 2-g oral dose of vitamin C. We were able to
confirm that this finding was also applicable in healthy,
younger smokers, in whom ingestion of 2 g of vitamin C
resulted in a threefold increase in plasma ascorbate concen-
tration and significant improvement in FMD after 2 h.
Mechanisms of vitamin C. Several mechanisms have been
proposed that may explain the short-term effects of vitamin
C on endothelial function. Vitamin C is a powerful water-
soluble antioxidant in human plasma (28) and it has been
suggested that it may enhance endothelial function by
scavenging oxygen-derived free radicals, including superox-
ide anion, which would otherwise interact with nitric oxide
and impair its vasoactive functions (29). However, very high
concentrations of vitamin C (.10 mmol/liter) are needed to
prevent the interaction of superoxide with nitric oxide (30).
Such high concentrations of vitamin C might be achievable
by intraarterial infusions of high dose vitamin C, as used in
previous studies (8–10,12,26,27), but not when given orally
(30). Therefore, it has been suggested that mechanisms
other than superoxide scavenging might be responsible for
the improvement in endothelial function seen after oral
administration of vitamin C (30).
The antioxidant activity of vitamin C is not restricted to
extracellular fluids. Vitamin C is actively transported into
cells and may play a role in the regulation of intracellular
redox state and antioxidant defences (31), possibly via
regulation of intracellular thiol species, such as glutathione.
Vitamin C preserves intracellular reduced glutathione con-
centration (31). This may improve nitric oxide action, since
depletion of glutathione has been shown to lead to de-
creased synthesis of nitric oxide (32), possibly through an
effect on the activity of nitric oxide synthase (33). Further-
more, increased availability of reduced thiol species has been
shown to stabilize nitric oxide (34) and to potentiate its
vasoactive effects (35). Furthermore, data from Jackson et al.
(30) support the idea that physiologic concentrations of
intracellular ascorbate, reported to be in the range of 1 to 2.5
mmol/liter (36), might be sufficient to compete in the
reaction between superoxide and nitric oxide. Thus, intra-
cellular sources of superoxide that impair nitric oxide might
be scavenged by concentrations of vitamin C that might be
possible with short-term oral supplementation (30).
Long-term studies with antioxidants. Of much greater
practical relevance in disease prevention, however, is the
study of longer-term effects of vitamin C on arterial func-
tion in asymptomatic but high risk subjects. Previous
long-term studies on the effects of antioxidant therapy on
endothelial function have been controversial. Hornig et al.
(26) studied the effects of vitamin C on conduit artery
endothelial function in patients with chronic heart failure
and observed a significant improvement in radial artery
FMD in a subset of five patients examined after four weeks
of high dose oral vitamin C supplementation (1 g twice
daily). Furthermore, four-week combination therapy of oral
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vitamin C (1 g/d) and vitamin E (400 IU twice daily) has
been shown to improve brachial artery FMD in children and
adolescents with endothelial dysfunction due to hereditary
hypercholesterolemia (37).
Recently, Gokce et al. (38) studied the effects of short-
(2 h) and medium-term (30 days) oral vitamin C therapy on
endothelial function in patients with established coronary
artery disease. Contrary to the present study, these authors
found a sustained beneficial effect on endothelial function
after one month of therapy. Different study population, a
different dose of vitamin C and the shorter duration of the
intervention period may explain the apparently discrepant
results. Regarding vitamin E therapy, Heitzer et al. (20)
have documented a beneficial effect of this antioxidant on
vascular endothelial function only among smokers with
hypercholesterolemia (but not in those with either risk
factor alone). In the present study, there were only four
smokers who had LDL cholesterol levels .4.1 mmol/liter
(160 mg/dl). This number of subjects was too small to
perform a meaningful subgroup analysis on the effects of
vitamin C therapy in hypercholesterolemic smokers.
In contrast to the positive findings reviewed above,
Simons et al. (39) recently documented a lack of benefit of
long-term oral vitamin E therapy on arterial endothelial
function in the healthy elderly. Similarly, Gilligan et al. (40)
did not observe improvement in endothelial function in
hypercholesterolemic subjects after one month of therapy
with a combination of antioxidant vitamin supplements
(daily: beta-carotene 30 mg, vitamin C 1 g, vitamin E 800
UI), despite significant reduction in the ex vivo oxidizability
of LDL. Differences in patient characteristics and antioxi-
dant doses might explain these discrepancies. Surprisingly,
however, this current study is the first report of which we are
aware to describe the vascular effects of vitamin C therapy
for over one month.
Vitamin C might be thought to be particularly effective in
healthy young cigarette smokers, in whom ascorbate levels
are known to be decreased (6). Indeed in our study, before
treatment, the smokers had low plasma ascorbate levels
(42 6 21 mmol/liter) compared with previously reported
normal values (50 to 150 mmol/liter) (19). After eight weeks
supplementation with oral vitamin C (1 g daily), there was
a sustained increase in the plasma ascorbate levels to well
within the normal range (92 6 32 mmol/liter). Despite this,
however, and the encouraging vascular effects observed after
2 h, there was no significant improvement in endothelial
function at eight weeks. Higher oral doses of vitamin C are
unlikely to have been more effective, as bioavailability is
maximal at a dose of 1 g/d; at higher doses, the extra
ascorbate appears in the urine (15). The reasons for this lack
of effect are unclear, but may indicate the reduction in the
bioactivity of vitamin C associated with prolonged therapy.
In summary, short-term oral administration of antioxi-
dant vitamin C markedly improved endothelial function in
smokers, but there was no significant beneficial effect
observable after a further eight weeks of treatment. Our
results therefore suggest that oxidative stress may contribute
to the endothelial impairment in smokers. The lack of
sustained effect, however, implies the existence of intracel-
lular and/or extracellular adaptive mechanisms, and there-
fore discourages the daily use of vitamin C for vascular
protection in smokers with established endothelial dysfunc-
tion.
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